Aardvark Therapeutics, Inc. Common Stock

Aardvark Therapeutics, Inc. Common Stock

AARD - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$20.19M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Aardvark Therapeutics, Inc. Common StockAardvark Therapeutics, Inc. Common Stock-0.4--126%--
$2.40

Target Price by Analysts

160.1% upsideAardvark Therapeutics Common Stock Target Price DetailsTarget Price
$2.14

Current Fair Value

131.6% upside

Undervalued by 131.6% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$20.19 Million
Enterprise Value$-39,570,345.00
Earnings per Share$-2.64
Beta3.81
Outstanding Shares21,886,684

Return

Return on Equity-126.30%ROE
Return on Assets-112.28%
Return on Invested Capital-126.87%

Valuation & Multiples

P/E Ratio-0.4P/E Ratio
PEG-2.26PEG
Price to Sales-Price to Sales
Price to Book Ratio0.46Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT0.42
Enterprise Value to Net Income0
Total Debt to Enterprise-0.02
Debt to Equity0.01Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 13, 2026
EPS
-$0.88
Est. -$0.72
Revenue Estimate
-
Consensus analyst estimate

Next Earnings Call

Expected Date
March 22, 2027
EPS Estimate
-$0.76
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 2.14, the ratio is above 1, so institutions hold more puts than calls. That is a more cautious stance.

Put/Call Ratio2.1412▼ 345.75%
Total Calls25,500▲ 73.47%
Total Puts54,600▼ 33.66%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %43.64%▲ 0.46%
Total Invested$50.24M▼ 7.56%
Investors Holding72▼ 3.00%

About Aardvark Therapeutics, Inc. Common Stock

28 employees
CEO: Tien-Li Lee

Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate hom...

Aardvark Therapeutics Common Stock Insider Information FAQ

Stockcircle shows 2 open-market insider sales for Aardvark Therapeutics Common Stock in the last six months from SEC Form 4 reports by executives, directors, and other insiders.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.

Questions & Answers